Roche to invest 5 billion roubles in development of new drugs in Russia

27 June 2017

Swiss pharma giant Roche (ROG: SIX) has signed an agreement with IM Sechenov First Moscow State Medical University, Russia’s oldest and the largest national medical higher educational institution, on investing 5 billion roubles ($84 million) on conducting R&D activities and the development of new drugs in Russia, reports The Pharma Letter’s local correspondent.

This has already been confirmed by Nenad Pavletich, general director of Roche Russia. According to him, a priority will be given to carrying out joint fundamental and applied researches, as well as clinical approbation and assessment of the quality of health technologies in the field of neurology and oncology.

It is planned that at the initial stage particular attention will be paid to studies of drugs for the treatment of idiopathic pulmonary fibrosis and with malignant tumors of the lymphoid system.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK